Human Papilloma Virus (HPV) detection and typing
HPV is the main causative agent of cervical cancer. There are more than 100 types of HPV and approximately 25 affect the female and male genital tract, making it the sexually transmitted disease more prevalent in sexually active people. About 15 types of HPVs are classified as high-risk oncogenic viruses and are found in more than 99% of cases of cervical cancer. Detection through screening techniques has become the primary prevention tool for cervical cancer.
As early as 2012, the American Cancer Society guidelines for the early detection of cervical cancer included the HPV DNA test as a method to be used in conjunction with cytology for screening and investigation of abnormal cytological findings, and this recommendation is widely incorporated into clinical practice nowadays. In addition, the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology published in 2015 guidelines that endorsed screening with an HPV test isolated (no cytology) every 3 years for women aged ≥25 years, recommending the use of different clinical approaches for the management of patients infected with different HPV genotypes identified by virus genotyping.
The F-HPV TYPING examination consists of the detection and genotyping of HPV by Fluorescent Multiplex Typing. This study evaluates the following types of low-risk (6, 11) and high-risk HPV (16, 18, 31, 33, 35, 39 , 45, 51, 52, 56, 58, 59, 66, 68).
Indicated in the following cases:
• Screening of primary cervical cancer in women from the age of 30, along with cytology.
• Patients with dubious cytology.
• Patients with mild to moderate precancerous lesions, in order to predict their regression, persistence or progression.
• Patients who have been treated for cervical intraepithelial neoplasia (CIN) or cervical carcinoma as part of their follow-up.
Multiplex-fluorescent PCR (MF-PCR)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis. COMPLETE:
• Objective and detailed results report.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• For an optimized result, it is preferable that the woman is not in the menstrual period.
• Pregnant women can perform the test until the 10th gestational week.
• If the patient has a gestational age greater than 10 weeks, it is recommended that the test be performed 6 months after delivery.
• If the patient has previously collected a cytological sample or colposcopy in acetic acid, it is recommended to obtain the sample for after 3 weeks.
• In cases in which the woman had colposcopy with iodine, wait 6 months.